Novel bacteriophage lysin with broad lytic activity protects against mixed infection by streptococcus pyogenes and methicillin-resistant staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2743-2750

  Gilmer, Daniel B ^a   Schmitz, Jonathan E ^a,b   Euler, Chad W ^a   Fischetti, Vincent A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; ANTIBIOTIC AGENT; BACTERIOPHAGE LYSIN; CYSTEINE HISTIDINE AMINOPEPTIDASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FREEZE THAWING; GROUP A STREPTOCOCCAL INFECTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; STREPTOCOCCUS SUIS; TEMPERATURE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; COINFECTION; DISEASE MODELS, ANIMAL; ENZYMES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PHAGES; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

EID: 84877859662     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02526-12     Document Type: Article

References (42)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5:685-694.
2. Swedo SE, Leonard HL, Mittleman BB, Allen AJ, Rapoport JL, Dow SP, Kanter ME, Chapman F, Zabriskie J. 1997. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am. J. Psychiatry 154:110-112.
3. Parker MT, Tomlinson AJ, Williams RE. 1955. Impetigo contagiosa; the association of certain types of Staphylococcus aureus and of Streptococcus pyogenes with superficial skin infections. J. Hyg. (Lond.) 53:458-473.
4. Bisno AL, Brito MO, Collins CM. 2003. Molecular basis of group A streptococcal virulence. Lancet Infect. Dis. 3:191-200.
5. White A, Smith J. 1963. Nasal reservoir as the source of extranasal staphylococci. Antimicrob. Agents Chemother. 161:679-683.
6. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 5:751-762.
7. Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 13:1840-1846.
8. Tiemersma EW, Bronzwaer S, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, Grundman H. 2004. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg. Infect. Dis. 10:1627-1634.
9. Laupland KB, Ross T, Gregson DB. 2008. Staphylococcus aureus blood-stream infections: Risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J. Infect. Dis. 198:336.
10. Centers for Disease Control and Prevention. 1999. From the Centers for Disease Control and Prevention. Four pediatric deaths from communityacquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. JAMA 282:1123-1125.
11. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS. 1998. Community-acquired methicillin- resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-598.
12. Zetola N, Francis JS, Nuermberger EL, Bishai WR. 2005. Communityacquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect. Dis. 5:275-286.
13. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23:616-687.
14. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-1453.
15. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. 2009. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 106:5883-5888.
16. O'Flaherty S, Ross RP, Coffey A. 2009. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol. Rev. 33:801-819.
17. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 11:393-400.
18. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. U. S. A. 98:4107-4112.
19. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172.
20. Fischetti VA. 2005. Bacteriophage lytic enzymes: Novel anti-infectives. Trends Microbiol. 13:491-496.
21. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:1603-1612.
22. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49:111-117.
23. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J. Bacteriol. 187:7161-7164.
24. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Yagyu K, Muraoka A, Sugai M, Hiramatsu K, Honke K, Matsuzaki S. 2007. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage ?MR11. J. Infect. Dis. 196: 1237-1247.
25. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. 2006. PlyC: A multimeric bacteriophage lysin. Proc. Natl. Acad. Sci. U. S. A. 103:10765-10770.
26. Wang Y, Sun JH, Lu CP. 2009. Purified recombinant phage lysin LySMP: An extensive spectrum of lytic activity for swine streptococci. Curr. Microbiol. 58:609-615.
27. Wiegand I, Hilpert K, Hancock RE. 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3:163-175.
28. Rouse MS, Rotger M, Piper KE, Steckelberg JM, Scholz M, Andrews J, Patel R. 2005. In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3187-3191.
29. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA. 2011. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and-sensitive Staphylococcus aureus strains. Antimicrob. Agents Chemother. 55:738-744.
30. Schleifer KH, Kandler O. 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 36:407-477.
31. Sieradzki K, Tomasz A. 2003. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J. Bacteriol. 185:7103-7110.
32. Fenton M, Ross RP, McAuliffe O, O'Mahony J, Coffey A. 2011. Characterization of the staphylococcal bacteriophage lysin CHAP(K). J. Appl. Microbiol. 111:1025-1035.
33. Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG, Donovan DM. 2009. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol. Lett. 294:52-60.
34. Hermoso JA, Monterroso B, Albert A, Galan B, Ahrazem O, Garcia P, Martinez-Ripoll M, Garcia JL, Menendez M. 2003. Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. Structure 11:1239-1249.
35. Xu Q, Abdubek P, Astakhova T, Axelrod HL, Bakolitsa C, Cai X, Carlton D, Chen C, Chiu HJ, Chiu M, Clayton T, Das D, Deller MC, Duan L, Ellrott K, Farr CL, Feuerhelm J, Grant JC, Grzechnik A, Han GW, Jaroszewski L, Jin KK, Klock HE, Knuth MW, Kozbial P, Krishna SS, Kumar A, Lam WW, Marciano D, Miller MD, Morse AT, Nigoghossian E, Nopakun A, Okach L, Puckett C, Reyes R, Tien HJ, Trame CB, van den Bedem H, Weekes D, Wooten T, Yeh A, Hodgson KO, Wooley J, Elsliger MA, Deacon AM, Godzik A, Lesley SA, Wilson IA. 2010. Structure of the gamma-D-glutamyl-L-diamino acid endopeptidase YkfC from Bacillus cereus in complex with L-Ala-?-D-Glu: Insights into substrate recognition by NlpC/P60 cysteine peptidases. Acta Crystallogr. F Struct. Biol. Cryst. Commun. 66:1354-1364.
36. Morens DM, Taubenberger JK, Fauci AS. 2009. The persistent legacy of the 1918 influenza virus. N. Engl. J. Med. 361:225-229.
37. Brundage JF, Shanks GD. 2007. What really happened during the 1918 influenza pandemic? The importance of bacterial secondary infections. J. Infect. Dis. 196:1717-1718.
38. Brundage JF, Shanks GD. 2008. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg. Infect. Dis. 14:1193-1199.
39. Hussell T, Wissinger E, Goulding J. 2009. Bacterial complications during pandemic influenza infection. Future Microbiol. 4:269-272.
40. Hudson IR. 1994. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: A review of recent experience. J. Hosp. Infect. 27:81-98.
41. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889.
42. Robinson JM, Hardman JK, Sloan GL. 1979. Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus. J. Bacteriol. 137:1158-1164.